The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The East Carolina Breast Center phase II trial of neoadjuvant metronomic chemotherapy in triple-negative breast cancer.
R. E. Raab
No relevant relationships to disclose
P. R. Walker
No relevant relationships to disclose
L. S. Bellin
No relevant relationships to disclose
J. H. Wong
No relevant relationships to disclose